Morbid obesity attenuates the skeletal abnormalities associated with leptin deficiency in mice

Russell T Turner1, Kenneth A Philbrick2, Carmen P Wong2

  • 1Skeletal Biology LaboratorySchool of Biological and Population Health SciencesCenter for Healthy Aging ResearchBiostatisticsSchool of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon 97331, USA Skeletal Biology LaboratorySchool of Biological and Population Health SciencesCenter for Healthy Aging ResearchBiostatisticsSchool of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon 97331, USA.

Insights

Leptin deficiency in mice causes skeletal abnormalities, but morbid obesity exacerbates these effects. Reducing food intake in leptin-deficient mice attenuated skeletal issues, suggesting obesity worsens bone problems.

Area of Science:

  • Endocrinology
  • Bone Biology
  • Metabolic Research

Background:

  • Leptin deficiency in ob/ob mice leads to morbid obesity, low bone mass, and osteopetrosis.
  • Disentangling skeletal effects of leptin deficiency from obesity is crucial for understanding bone metabolism.

Purpose of the Study:

  • To differentiate the skeletal consequences of leptin deficiency from those of morbid obesity.
  • To investigate bone mass, architecture, gene expression, and bone turnover in WT, ad libitum-fed ob/ob, and pair-fed ob/ob mice.

Main Methods:

  • Mice were housed at thermoneutrality (32°C) from 6 to 18 weeks of age.
  • Evaluated bone mass, architecture (femur length, BMC, BMD, cortical thickness), gene expression, and bone turnover indices.
  • Compared WT, ad libitum-fed ob/ob, and pair-fed ob/ob mice.

Main Results:

  • ob/ob mice exhibited higher weight, abdominal WAT, and hyperglycemia compared to WT mice.
  • ob/ob mice showed reduced femur length, BMC, BMD, and cortical thickness, with higher cancellous BV fraction but lower bone formation and resorption.
  • Pair-fed ob/ob mice had reduced weight, WAT, and glucose levels, with attenuated skeletal abnormalities compared to ad libitum-fed ob/ob mice, but increased bone marrow adiposity and calcified cartilage.

Conclusions:

  • Leptin deficiency causes skeletal abnormalities, including reduced bone mass and altered turnover.
  • Morbid obesity associated with leptin deficiency exacerbates skeletal abnormalities.
  • Interventions to reduce obesity may mitigate skeletal deficits in leptin-deficient states.

Related Concept Videos

Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
11.3K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
437